Page 72 - Sohini Das

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe

Covid vaccination of eligible children a priority, PM Modi tells CMs

Special campaigns needed in schools; parents worried about increased number of cases

Dr Batra's to double clinic count in FY23 on spike in homoeopathy demand

Eyes 225 centres, entry into smaller towns; Firm says clinics are back to pre-Covid-19 footfall levels, with 30% YoY growth in patients in FY22

Pfizer's anti-Covid pill Paxlovid could be available in India next week

This assumes significance as Covid cases are on the rise in the country, especially in the National Capital Region (NCR)

Covid-19: Omicron BA.2.12.1 has mutation akin to Delta, says virologist

Doctors say Covid cases rising, but not very severe patients yet

Awareness holds key to success of AYUSH mark, says industry

PM Modi had said that India would soon introduce the AYUSH mark, which will give authenticity to quality AYUSH products of the country.

Omicron variant found in NCR, likely to have caused spike in Covid cases

BA.2.12.1 is a variant of the virus's Omicron strain and was found in 60% of total samples tested in Delhi

Indian drug firms get a shot in the arm in $12-bn Australian drug market

India has over 750 USFDA approved plants and over 4000 products which are approved by either the US or EU or any other stringent regulator.

Covid-19 cases spike across India; Delhi brings back mask rule

233 out of 727 districts in India report rise in positivity rate between April 16 and 19

Cost pressure likely to weigh on pharma companies' margins in Q4

Among Indian firms, Edelweiss feels that Cipla (respiratory) and Sun Pharma (specialty) are better placed to tide the price erosion

Ocugen to commercialise Covaxin in Mexico, working on US market too

Covaxin has EUA in Mexico for use in adults; data submitted for EUA for children aged 2-18 years

Covid concerns return with cases on the rise; DDMA may make masks mandatory

As on April 16, Delhi-NCR accounted for 52.5 per cent of the country's total cases - up from 11.8 per cent on April 1

Dip in demand for Covid medicines takes a toll on drug sales in March

Covid related drugs contributed 40% of the pharma market last year

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

Paid Covid-19 booster shots: Experts divided on govt intervention

Centre may have to step in to ensure universal coverage, some say; also call for shift in focus to strengthen surveillance, testing and gathering data

Boosters for all: Pvt hospitals in a bind over new pricing, old vax stocks

Some Kolkata hospitals have decided to go with the new pricing from Monday on the basis of discussions.

Govt okays booster Covid shot for all adults at private centres from Apr 10

Around 22.8 mn precaution or booster dose have been administered to healthcare and frontline workers along with senior citizens after the population segments opened up in the first week of January.

India's major drug players bet on new brand launches, shows data

Industry insiders say brand launches are the lifeline of the pharma industry, and ensure steady volume growth and market share

INSACOG testing sewage water samples across 55 sites to detect Sars-CoV-2

'This is called environmental surveillance, and India has done this during the polio campaign,' said N K Arora, co-chair, INSACOG

India's 1st Covid variant XE case in Mumbai: Civic body and Centre differ

BMC declares results of 11th genome sequencing done by it. One sample tested positive for XE strain, another tested positive for Kappa variant